Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Emergent BioSolutions Inc. Common Stock (NY:EBS)

8.258 +0.188 (+2.32%)
Streaming Delayed Price Updated: 9:32 AM EDT, Jun 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Emergent BioSolutions Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
News headline image
Emergent BioSolutions Supports Victoria’s Voice Foundation’s National Naloxone Awareness Day to Help Save Lives from Opioid Overdose
Efforts focus on increasing awareness, expanding access to lifesaving NARCAN® Nasal Spray and reaching more communities with educational initiatives and resources 
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Support U.S. Biodefense Strategy
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions to Participate in Upcoming Investor Conferences
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions (NYSE:EBS) Surges After Q1 Earnings Beat and Raised Profit Outlook ↗
Via Chartmill
Topics Earnings
Emergent BioSolutions Inc (NYSE:EBS) Shares Tumble on Weak Q4 Results and Cautious 2026 Outlook ↗
Via Chartmill
News headline image
Emergent BioSolutions Receives Saudi Food and Drug Authority Approval for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live]
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent (EBS) Q1 2026 Earnings Transcript ↗
Emergent (EBS) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Emergent BioSolutions Reports First Quarter 2026 Financial Results
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Receives Approval from Singapore Health Sciences Authority for Expanded Indication of ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) to Include Mpox
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Partners with Professional Baseball Player Davis Schneider to Raise Awareness of NARCAN® Nasal Spray Among Canadians and Help Save Lives
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions and Substipharm Biologics Announce Strategic Manufacturing Partnership to Support Japanese Encephalitis Vaccine in the United States
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent (EBS) Q4 2025 Earnings Transcript ↗
Emergent (EBS) Q4 2025 Earnings Transcript 
Via The Motley Fool
Topics Bonds
News headline image
Emergent BioSolutions to Report First Quarter 2026 Financial Results on April 30, 2026
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Successfully Refinances Term Loan, Amends Asset-backed Loan Facility and Increases Financial Flexibility
Refinancing extends maturities, reduces interest expense and positions Emergent for durable, long-term growth as part of its multi-year transformation plan 
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Partners with British Columbia to Supply NARCAN® Nasal Spray for the Launch of the Expanded BC Take Home Naloxone Program
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Launches New NARCAN® Nasal Spray Carrying Case and Multipacks Alongside College Campus Outreach to Expand Opioid Overdose Preparedness
New product offerings and educational initiative, Ready to Rescue, aim to increase access and adoption of NARCAN® Nasal Spray to empower communities to save a life in an opioid overdose emergency 
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Participates in Upcoming International Preparedness Conferences
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Secures over $60 Million in New Contract Award with the U.S. Government and New Orders with an International Government Partner for Smallpox Medical Countermeasures
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Announces Appointment of John D. Fowler, Jr. to Board of Directors
From Emergent BioSolutions
Via GlobeNewswire
What's going on in today's pre-market session ↗
Via Chartmill
News headline image
Why Did Emergent Biosolutions Stock Tumble 20% After-Hours Today? ↗
The board authorized a new $50 million share repurchase program running through March 2027. 
Via Stocktwits
Topics Earnings
Wondering what's happening in today's after-hours session? ↗
Via Chartmill
News headline image
Emergent BioSolutions Reports Fourth Quarter and Full Year 2025 Financial Results
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Announces Approximately $140 Million in Contract Awards with the Government of Canada, Strengthening Canada’s Leadership in Health Preparedness
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Announces New $50 Million Stock Repurchase Program
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Receives U.S. FDA Approval of Supplemental New Drug Application (sNDA) for NARCAN® Nasal Spray Multipacks
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Why Did EBS Stock Fall 13% Today? ↗
New York State Attorney General Letitia James inked a settlement with Emergent under which the company will pay $900,000 in penalties. 
Via Stocktwits
Topics Law Enforcement Lawsuit
News headline image
Emergent BioSolutions Receives U.S. FDA Approval on Supplemental New Drug Application for NARCAN® Nasal Spray to be Packaged in a New Carrying Case, Making Life-Saving Naloxone More Accessible for Everyday Preparedness
From Emergent BioSolutions
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.